Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 6/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239323 | 0.91 | SLC6A4 (0.43) | SLC6A4ACACBVNN1HDAC6CLK4 | |
| SCHEMBL20239291 | 0.87 | ACACB (0.42) | ACACBVNN1HDAC6NPC1RAB9A | |
| SCHEMBL20239213 | 0.87 | TAAR1 (0.41) | VNN1HDAC6CLK4DYRK1APTGDR | |
| SCHEMBL20239155 | 0.86 | ACACB (0.51) | ACACBVNN1MAP2K7 | |
| SCHEMBL20239218 | 0.84 | DGAT2 (0.47) | VNN1HDAC6CLK4NPC1RAB9A | |
| SCHEMBL20259113 | 0.82 | ACACB (0.47) | ACACBVNN1MAP2K7 | |
| SCHEMBL20472855 | 0.82 | GPR39 (0.44) | VNN1CLK4NPC1RAB9AKMT2A | |
| SCHEMBL20239342 | 0.81 | CA12 (0.50) | VNN1PTGDRNPC1RAB9AKMT2A | |
| SCHEMBL20239251 | 0.80 | VNN1 (0.44) | VNN1HDAC6KMT2AMAP2K7 | |
| SCHEMBL20239143 | 0.77 | VNN1 (0.44) | VNN1HDAC6CLK4DYRK1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | SLC6A4 1358/4885ACACB 152/4885VNN1 3148/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | SLC6A4 1459/4885ACACB 152/4885VNN1 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.